Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of tamoxifen in preparation of medicament for protecting retina photoreceptor cells

A technology of tamoxifen and photoreceptor cells, which is applied in the field of medicine, can solve problems such as disrupting the menstrual cycle, increasing the risk of uterine cancer, and reducing weight, and achieves the effects of improving the electroretinogram waveform, increasing the survival rate, and reducing the apoptosis rate

Active Publication Date: 2018-07-20
王晓琳
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Tamoxifen has certain side effects, such as disrupting the menstrual cycle, losing weight, and increasing the risk of uterine cancer, stroke, or pulmonary embolism
There is no report on the improvement of subretinal hemorrhage by tamoxifen

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of tamoxifen in preparation of medicament for protecting retina photoreceptor cells
  • Application of tamoxifen in preparation of medicament for protecting retina photoreceptor cells
  • Application of tamoxifen in preparation of medicament for protecting retina photoreceptor cells

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] C57BL / 6 mice, 17 2-month-old mice, were divided into 2 groups: 10 mice in the experimental group, 5 male mice and 5 female mice; 7 mice in the control group, 4 male mice and 3 female mice.

[0041] The treatment group had a normal diet, and administered tamoxifen to the mice at a dose of 400 mg per kilogram of body weight, once every 2 days,

[0042] The control group had a normal diet, and the mice were given the same amount of excipients by gavage, once every 2 days.

[0043] On the 4th day, the autologous blood from the tail of the mouse was injected under the retina of the right eye, and after another 4 days, the right eye was taken and embedded in agar for sectioning for testing. The testing included:

[0044] 1: TUNEL detection

[0045] DAPI (4,6-Diamidino-2-phenylindole, 4',6-diamidino-2-phenylindole) was used to stain cell nuclei, and Roche's apoptosis detection kit was used to detect cell apoptosis (principle: terminal Deoxynucleotidyl transferase deoxyuridin...

Embodiment 2

[0055] Four C57BL / 6 mice, 2 months old, were divided into 2 groups; 2 mice in the experimental group, 1 male mouse and 1 female mouse; 2 mice in the control group, 1 male mouse and 1 female mouse.

[0056] When the mice were not treated, detect the dark adaptation electroretinogram (scotopicelectroretinogram, ERG) of the left and right eyes of the mice, and the light stimulation intensity of ERG: 10cd.s / m 2 .

[0057] Thereafter, the treatment group took a normal diet and administered tamoxifen to the mice at a dose of 80 mg per kilogram of body weight once a day.

[0058] The control group had a normal diet, and the mice were gavaged with the same amount of excipients once a day.

[0059] After 6 days, detect the ERG of the left and right eyes of the mouse again, and the intensity of light stimulation: 10cd.s / m 2 .

[0060] The results showed that no matter male or female rats, after administration of tamoxifen, ERG changes (the arrow indicates the change), which should be...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medicaments, in particular to application of tamoxifen in preparation of a medicament for protecting retina photoreceptor cells. According to the application, mouse models with subretinal hemorrhage caused by an autologous blood injection mode are adopted; research shows that the survival rate of the retina photoreceptor cells which are in contact with blood can be improved, the apoptosis rate of the retina photoreceptor cells can be reduced, and the thickness of a retina outer nuclear layer can be maintained by giving the tamoxifen. A protectingeffect on the retina photoreceptor cells can be applied in a protective manner, namely, the tamoxifen is used when new vessels do not burst. Based on experimental results, the protecting effect can also be achieved on surviving retina photoreceptor cells in a retina even after bleeding. The tamoxifen can change an electroretinogram waveform of a normal mouse, which is one of the mechanisms for protecting the retina photoreceptor cells.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the application of tamoxifen or its metabolites in human body in the preparation of drugs for protecting retinal photoreceptor cells. Background technique [0002] Subretinal hemorrhage is a clinical phenomenon, not an independent eye disease, but a type of fundus hemorrhage. Subretinal hemorrhage occurs in various diseases, such as age-related macular degeneration (Age-related macular degeneration, AMD) or polypoidal choroidal vasculopathy (Polypoidal choroidal vasculopathy, PCV). Fundus hemorrhage includes subretinal hemorrhage, vitreous hemorrhage, and retinal hemorrhage. Vitreous hemorrhage is often caused by rupture of retinal neovascularization, which is more common in advanced diabetic retinopathy and retinal branch or central vein occlusion. Retinal hemorrhage is more common in early diabetic retinopathy and retinal branch or central vein occlusion. [0003] Subretina...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/138A61P27/02
CPCA61K31/138
Inventor 不公告发明人
Owner 王晓琳
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com